Four Years, One Lost Prime: What the Trimetazidine Ledger Records for Parikshit Somani

Three adjectives sit in the tribunal's ruling that no athlete wants on file — “scientifically implausible”, “highly speculative”, “unconvincing”. Parikshit Somani's food-contamination defence died on exactly those three words. Then came the number: four years, running to September 2029. A hearing in August, an announcement on Wednesday.

The first line of Wednesday's ruling is simple. The second is brutal. When Somani returns he will be 30, and his ranking will start from zero. The only competitive figure in the source report is a doubles career-high of No. 256, reached at 26.

Alongside years of watching matches, I have kept an injury ledger. In 2026 I brought a spreadsheet to Russia and left with a diaspora; in 2026, Empty Stadiums, Open Notebook, I built a return-to-play register across fourteen leagues and eleven hundred matches; in the Tokyo heat of 2026 I wrote up a pattern I called the abdominal flag, where athletes back from abdominal surgery inside ninety days re-injured at roughly triple the base rate. One line in my notebook keeps returning: every limp is a sentence; I read the grammar of pain.

Nobody is limping here. The grammar has to change — from pain to penalty. And the central sentence is about burden of proof, not about the length of the ban.

Tennis's anti-doping system runs under the World Anti-Doping Code, and trimetazidine is an S4-class metabolic modulator — a heart medication banned at all times. The operative phrase is “at all times”: in competition and out. That leaves almost no room for an “I didn't know” defence.

The adverse finding came at a lower-tier event in Astana, Kazakhstan, dated only as “last year” — no fixed date anywhere in the record. Read together, those two facts place the case at the base of the sport rather than in front of it. At Challenger or ITF level a player has no personal physio, no team doctor, no sports nutritionist; in many homes the family kitchen is the first source of medication. That is why this ruling is small through a player's lens and large through a governance lens.

The term adds another layer. A fixed September 2029 end date implies a defined ineligibility period, yet the calculation anchor — provisional suspension date or sample collection date — is not stated. It sounds technical. It matters practically, because in contamination cases the timeline often becomes the second-storey argument on appeal.

What the report omits says more still: singles ranking. Only the doubles figure is cited. When a report reaches for a doubles ranking as a player's best credential, the singles profile usually sits lower. That is an inference, not a claim — but the direction is useful for accounting.

So why did the contamination defence collapse?

Because there is a gap between what the Code says and what a tribunal actually demands. The Code allows a sanction to be eliminated if an athlete proves “no fault or negligence”. In practice that means doing more than sketching a plausible route of ingestion: it means proving which food, who bought it, what was in the box. Scientific proof means laboratory-grade accounting, where conjecture has no place and only explanation counts. The tribunal's language says the defence never reached that bar.

This is where the ledger metaphor hits a real limit. A doping sample now travels through a chain-of-custody ledger — seal, barcode, laboratory, signature — and that ledger is immutable. The athlete's defence, meanwhile, is built in the opposite direction: in a private, unwritten, almost unreconstructable place — a family kitchen. One side has a ledger, the other has memory. The hearing happens between them, and the ledger nearly always wins.

The precedent chain is clear too. Same substance, same outcome: Kamila Valieva's case also produced a four-year ban. Sun Yang's 2026 trimetazidine case is cited as a substance reference, not a factual match. Holding that distinction matters, or two different procedural histories collapse into one. Tribunal language has been tilting one way of late — trimetazidine food-contamination narratives are read with heightened scepticism. This is not an isolated ruling.

The scope of the sanction is broad: no playing, no coaching, no attendance at ITF, ATP, WTA, Grand Slam or national-federation events. That closes the parallel-career door for four years — no coaching, no administration, no organising.

Now the part I find hardest to write. Four years sounds like an enormous sanction. But a doubles career-high of No. 256 at 26 already sits well below the main-tour cut. The ranking loss is therefore small; the career loss is close to final. And the largest piece is missing from the earlier facts: Protected Ranking relief, which injury layoffs can unlock, is generally unavailable for doping bans. On return, everything must be rebuilt from zero through qualifying.

Written into my ledger, the case reads: Player — a doubles-leaning base-tier professional. Competitive loss — significant, but already marginal. Institutional loss — zero. Governance signal — large.

And here is the contrarian angle. Anti-doping enforcement is toughest exactly where support is thinnest. At the base tier there is no experienced nutritionist, no budget to test supplements, and verification of a drug's exact name often rests with a family member. Yet the proof demanded is laboratory-grade, on near-zero resources. Somani is not being excused — the tribunal found him culpable, and the ruling says so. But when a system places its heaviest evidentiary burden on its weakest players, honesty is preserved at the cost of a pipeline of destruction.

The Valieva comparison is its own trap. The source report is explicit that the similarity lies in the type of explanation, not in the facts. Media routinely drop that nuance and merge the two into one case. My ledger keeps two separate columns: same substance, different procedure.

Coming from the injury side, I notice one asymmetry. With injuries I can often say in advance when a player returns, because the game, the competition, the load — all of it is open. A doping case states the return date too, yet nobody runs the risk model, because the risk is not in the body; it is on paper. That gap I have never filled well with my own toolbox.

So the ledger does not close here. The tribunal decision is not final — an appeal route to the Court of Arbitration for Sport remains open. But the language of the ruling suggests an appeal on the same evidence is close to impossible, because the part that collapsed was not a question of law. It was a question of scientific foundation.

What to watch, then, is not rhetoric but a date. When the ITIA's published sanctions list fixes the exact start of the September 2029 term, the timeline fog clears. Then: whether Somani's name appears on the CAS case list. And finally, whether subsequent trimetazidine rulings land in the same shape — because only after three rulings, not one, does the boundary of this precedent become visible.

My probabilities: serving the full term is the most likely outcome; a reduction is unlikely; and without new scientific evidence, extremely unlikely. Supporters can spin the story another way, but a weakness entered into a ledger stays there like a firm handprint.

That is where the real question bends. If the next four years of a 26-year-old's career end against a sealed sample and a piece of paper, who is the system actually protecting — the sport, or the paper trail it leaves behind?